The aim of this study was to evaluate the effectiveness of a genital vibratory stimulation device in improving sexual function in women with arousal and orgasm disorders.
In this single-arm, prospective study, baseline and 1- and 3-month assessments were performed to evaluate women with sexual arousal and/or orgasmic disorders, who received therapy using a genital vibratory stimulation device. Sexual function, satisfaction, and distress were evaluated using the Female Sexual Function Index (FSFI), the Female Sexual Distress Scale, and the Female Intervention Efficacy Index questionnaires. Genital sensation was evaluated using quantitative sensory testing.
Seventy women, aged 19 to 64 years, were evaluated from October 2009 to August 2013. Forty-seven (67.1%) and 37 (52.9%) women completed 1- and 3-month follow-ups, respectively. The FSFI arousal and orgasm domain scores and total FSFI scores improved at 1 and 3 months (P < 0.001 for all outcomes). Mean (SD) total FSFI scores increased from 20.04 (4.65) (baseline) to 25.03 (5.21) (1 month) to 26.66 (5.42) (3 months; both Ps < 0.0001). Female Sexual Distress Scale scores reflected significantly decreased distress at 1 (P = 0.0006) and 3 (P < 0.0001) months compared with baseline and at 3 months compared with 1 month (P = 0.03). Neurological sensation was increased at all genital sites at 1 and 3 months (P < 0.0001 for all). After adjustment for age, there was a significant interaction between arousal domain scores and clitoral and right labial sensation. At 3 months, perceptions of increased vaginal lubrication, orgasm, and genital sensation were reported by 67.5%, 65.0%, and 82.5% of the participants. No major adverse events were noted.
Genital vibratory stimulation device use resulted in uniform improvements in sexual function, satisfaction, sexually related distress and genital sensation.
Genital vibratory stimulation devices improve sexual function and increase genital sensation in women with arousal and orgasmic disorders.
From the *Departments of Obstetrics and Gynecology, Yale School of Medicine, New Haven, CT; †University of Colorado, Aurora, CO; ‡Montefiore Medical Center, Bronx, NY; and §Department of Urology, Albert Einstein College of Medicine, Bronx, NY.
Reprints: Marsha K. Guess, MD, MS, Section of Urogynecology and Pelvic Reconstructive Surgery, Department of Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine, 310 Cedar St, New Haven, CT 06510. E-mail: firstname.lastname@example.org.
This work has been accepted as an oral poster at the American Urogynecologic Society/PFD Week October 13 to 17, 2015.
Supported in part by financial support from the Advanced Response Corporation. The company provided the devices and partial funding for the study. From the Advanced Research Corporation, M.K.G. received an unrestricted grant, and K.F. and O.A. received financial support. The sponsor had no involvement in the study design, data collection, data analysis, interpretation of the data, writing of the manuscript, or the decision to submit the report for publication.
The authors have declared they have no conflicts of interest.